deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03566199

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (PNOC015)

An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy

Sponsor: Midatech Pharma US Inc.

Conditions Diffuse Intrinsic Pontine Glioma
Interventions Convection-Enhanced Delivery (CED) Panobinostat Nanoparticle Formulation MTX110
Updated 15 times since 2018 Last updated: Feb 2, 2022 Started: May 22, 2018 Primary completion: Mar 31, 2021 Completion: Mar 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Intrinsic Pontine Glioma and is currently completed. Midatech Pharma US Inc. leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Jul 2020 · 5 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~May 2021 · 3 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Dec 2022 · 9 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 20 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1_PHASE2

  5. Mar 2022 — Dec 2022 [monthly]

    Completed PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Nov 2021 — Mar 2022 [monthly]

    Completed PHASE1_PHASE2

  2. May 2021 — Nov 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  3. Feb 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jul 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Feb 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jul 2018 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

May 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Midatech Pharma US Inc.
  • Pacific Pediatric Neuro-Oncology Consortium
  • Sabine Mueller, MD, PhD
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations